About Adjuvance Technologies
Adjuvance Technologies is a Healthcare company based in New York (United States) founded in 2009. Vaccine adjuvants are designed and manufactured for medical applications. Adjuvance Technologies has raised $13.37 million across 4 funding rounds from investors including NIH, HHS and Morningside. The company has 20 employees. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is ADJUVANCE TECHNOLOGIES INC. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Adjuvance Technologies was founded in 2009 and is headquartered in New York, United States. Focus is placed on the biotechnology sector, where adjuvant molecules for vaccines are developed and produced. Synthetic production methods for these adjuvants are commercialized, while a range of novel adjuvants targeting cancer and infectious diseases is created through proprietary technology. Operations center on advancing vaccine formulations in this field.
- Headquarters New York, United States
- Employees 20
- SectorsHealthcare
- Website adjuvancetechnologies.com
- Social LinkedIn
- Legal Name Adjuvance Technologies Inc.
- Total Equity Funding$13.37M (USD)
in 4 rounds
- Latest Funding Round$1.47M (USD), Grant
May 2020
- InvestorsNIH
& 2 more
- Employee Count20
Funding Insights of Adjuvance Technologies
Adjuvance Technologies has successfully raised a total of $13.37M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $1.47 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.37M
- Total Rounds 4
- Last Round Grant — $1.47M
- First Round $1.72M
(Jun 2014)
- Investors Count 3
All 4 funding rounds of Adjuvance Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2020 | $1.47M | Grant | – | – | |
| Nov 2019 | $10.66M | Series A | – | – | |
| Nov 2016 | $2.72M | Series A | – | – | |
| Jun 2014 | $1.72M | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Adjuvance Technologies
Adjuvance Technologies has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and Morningside.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by Morningside, a VC fund. | morningside.com | Newton, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for Adjuvance Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Adjuvance Technologies
3 dated milestones of Adjuvance Technologies across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Adjuvance Technologies is founded.
- Funding First funding round of $1.7M.
- Funding Latest funding round, Grant, of $1.5M.
Competitors of Adjuvance Technologies
Adjuvance Technologies has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Adjuvance Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Adjuvance Technologies (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Adjuvance Technologies
Complete news archive for Adjuvance Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adjuvance Technologies
Adjuvance Technologies was founded in 2009 and raised its 1st funding round 5 years after it was founded.
Adjuvance Technologies is headquartered in New York, United States. It is registered at New York, New York, United States.
Adjuvance Technologies is a funded company, having raised a total of $13.37M across 4 funding rounds to date. The company's 1st funding round was a Grant of $1.72M, raised on Jun 2014.
Adjuvance Technologies has 20 employees.
Adjuvance Technologies was founded in 2009 and is headquartered in New York, United States. Focus is placed on the biotechnology sector, where adjuvant molecules for vaccines are developed and produced. Synthetic production methods for these adjuvants are commercialized, while a range of novel adjuvants targeting cancer and infectious diseases is created through proprietary technology. Operations center on advancing vaccine formulations in this field.
Adjuvance Technologies has 3 investors. Key investors include NIH, HHS, and Morningside.
Adjuvance Technologies operates through Adjuvance Technologies Inc..